Search | Clinical Trials Finder

Conditions: Venous Thrombosis
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more

Conditions: Venous Thrombosis
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more

Conditions: Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions: Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 12,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 135
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years and older
Enrollment: 8,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more

Conditions: Pharmacokinetics, Bioavailability, Healthy Participants
Interventions: Rivaroxaban; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Atrial Fibrillation, Stroke, Embolism
Interventions: Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 14,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 295
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more

Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions: rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 86
States / cities: Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (BAY59-7939), Enoxaparin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 4,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Conditions: Healthy, Renal Insufficiency
Interventions: Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: COVID-19
Interventions: Rivaroxaban, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more

Conditions: Heart Failure, Coronary Artery Disease
Interventions: Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 5,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 115
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more

Conditions: Healthy Volunteers
Interventions: Cobicistat, Darunavir/Cobicistat, Rivaroxaban; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Standard of Care; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Peripartum Cardiomyopathy, Postpartum
Interventions: Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo; Drug
Lead sponsor: Dennis M. McNamara, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 64
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more

Conditions: Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions: Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prevention, Venous Thromboembolism
Interventions: Rivaroxaban (BAY59-7939), Enoxaparin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 2,457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more

Conditions: Peripheral Arterial Disease
Interventions: Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation (AF), Stroke
Interventions: Abelacimab, Rivaroxaban; Biological · Drug
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 28
States / cities: Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions: Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 15,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 73
States / cities: Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more

Conditions: Stroke
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 7,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 38
States / cities: Tucson, Arizona • Long Beach, California • Stanford, California + 32 more

Search by objective public record fields.

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Oral Rivaroxaban in Children With Venous Thrombosis

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Excretion of Rivaroxaban in Human Breast Milk

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)